A carregar...
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity
BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...
Na minha lista:
| Publicado no: | Arthritis Res Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/ https://ncbi.nlm.nih.gov/pubmed/28800777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|